This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the implications of the Madrigal program, offering compelling commentary from a group of eight panelists with varying perspectives and takeaways.

This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story. This conversation offers varying first impressions and perspectives from the group of eight.